journal
MENU ▼
Read by QxMD icon Read
search

Lancet Neurology

journal
https://www.readbyqxmd.com/read/28522181/safety-and-efficacy-of-edaravone-in-well-defined-patients-with-amyotrophic-lateral-sclerosis-a-randomised-double-blind-placebo-controlled-trial
#1
(no author information available yet)
BACKGROUND: In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population...
May 15, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28522180/edaravone-a-new-treatment-for-als-on-the-horizon
#2
Orla Hardiman, Leonard H van den Berg
No abstract text is available yet for this article.
May 15, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28499853/epilepsy-and-two-evolving-societies
#3
Adrian Burton
No abstract text is available yet for this article.
May 9, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28499852/withdrawal-of-antiepileptic-drugs-an-individualised-approach
#4
Jacqueline A French
No abstract text is available yet for this article.
May 9, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28483337/individualised-prediction-model-of-seizure-recurrence-and-long-term-outcomes-after-withdrawal-of-antiepileptic-drugs-in-seizure-free-patients-a-systematic-review-and-individual-participant-data-meta-analysis
#5
Herm J Lamberink, Willem M Otte, Ada T Geerts, Milen Pavlovic, Julio Ramos-Lizana, Anthony G Marson, Jan Overweg, Letícia Sauma, Luigi M Specchio, Michael Tennison, Tania M O Cardoso, Shlomo Shinnar, Dieter Schmidt, Karin Geleijns, Kees P J Braun
BACKGROUND: People with epilepsy who became seizure-free while taking antiepileptic drugs might consider discontinuing their medication, with the possibility of increased quality of life because of the elimination of adverse events. The risk with this action, however, is seizure recurrence. The objectives of our study were to identify predictors of seizure recurrence and long-term seizure outcomes and to produce nomograms for estimation of individualised outcomes. METHODS: We did a systematic review and meta-analysis, and identified eligible articles and candidate predictors, using PubMed and Embase databases with a last update on Nov 6, 2014...
May 5, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28460892/safety-and-efficacy-of-erenumab-for-preventive-treatment-of-chronic-migraine-a-randomised-double-blind-placebo-controlled-phase-2-trial
#6
Stewart Tepper, Messoud Ashina, Uwe Reuter, Jan L Brandes, David Doležil, Stephen Silberstein, Paul Winner, Dean Leonardi, Daniel Mikol, Robert Lenz
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is important in migraine pathophysiology. We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine. METHODS: This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migraine, enrolled from 69 headache and clinical research centres in North America and Europe...
April 28, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28460891/challenging-chronic-migraine-targeting-the-cgrp-receptor
#7
Maria Adele Giamberardino, Raffaele Costantini
No abstract text is available yet for this article.
April 28, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28460890/another-milestone-in-childhood-spinal-muscular-atrophy
#8
John H Wokke
No abstract text is available yet for this article.
April 28, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28460889/safety-and-efficacy-of-olesoxime-in-patients-with-type-2-or-non-ambulatory-type-3-spinal-muscular-atrophy-a-randomised-double-blind-placebo-controlled-phase-2-trial
#9
Enrico Bertini, Eric Dessaud, Eugenio Mercuri, Francesco Muntoni, Janbernd Kirschner, Carol Reid, Anna Lusakowska, Giacomo P Comi, Jean-Marie Cuisset, Jean-Louis Abitbol, Bruno Scherrer, Patricia Sanwald Ducray, Jeppe Buchbjerg, Eduardo Vianna, W Ludo van der Pol, Carole Vuillerot, Thomas Blaettler, Paulo Fontoura
BACKGROUND: Spinal muscular atrophy (SMA) is a progressive motor neuron disease causing loss of motor function and reduced life expectancy, for which limited treatment is available. We investigated the safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 SMA. METHODS: This randomised, double-blind, placebo-controlled, phase 2 study was done in 22 neuromuscular care centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK...
April 28, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28456480/imaging-the-ageing-brain-identifying-early-disease-or-opening-pandora-s-box
#10
Jonathan M Schott
No abstract text is available yet for this article.
April 26, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28434855/health-care-use-before-a-first-demyelinating-event-suggestive-of-a-multiple-sclerosis-prodrome-a-matched-cohort-study
#11
José M A Wijnands, Elaine Kingwell, Feng Zhu, Yinshan Zhao, Tanja Högg, Karen Stadnyk, Okechukwu Ekuma, Xinya Lu, Charity Evans, John D Fisk, Ruth Ann Marrie, Helen Tremlett
BACKGROUND: Degenerative processes in neurodegenerative diseases can start years before clinical manifestation. We aimed to establish whether a multiple sclerosis prodromal period exists by examining patterns of health-care use before a first demyelinating event. METHODS: In this matched cohort study, we used data from linked health administrative and clinical databases from four Canadian provinces (British Columbia, Saskatchewan, Manitoba, and Nova Scotia) to compare hospital, physician, and prescription use data from people with multiple sclerosis and matched general population controls in the 5 years before the first demyelinating disease claim (health administrative index date) or clinically reported symptom onset (clinical index date)...
April 20, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504111/olfactory-dysfunction-in-neurodegenerative-diseases-is-there-a-common-pathological-substrate
#12
REVIEW
Richard L Doty
In patients with neurodegenerative diseases, there is a spectrum of smell dysfunction ranging from severe loss, as seen in Alzheimer's disease and Parkinson's disease, to relatively little loss, as seen in progressive supranuclear palsy. Given the ubiquitous but varying degrees of olfactory dysfunction among such diseases, it is conceivable that differential disruption of a common primordial neuropathological substrate causes these differences in olfactory function. For example, the amount of damage to forebrain neurotransmitter and neuromodulator circuits, most notably those involving cholinergic transmission, appears to be correlated with quantitative smell test scores across a wide range of neurodegenerative diseases...
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504110/neurological-consequences-of-obesity
#13
REVIEW
Phillipe D O'Brien, Lucy M Hinder, Brian C Callaghan, Eva L Feldman
The high prevalence of obesity is associated with an enormous medical, social, and economic burden. The metabolic dysfunction, dyslipidaemia, and inflammation caused by obesity contribute to the development of a wide variety of disorders and effects on the nervous system. In the CNS, mild cognitive impairment can be attributed to obesity-induced alterations in hippocampal structure and function in some patients. Likewise, compromised hypothalamic function and subsequent defects in maintaining whole-body energy balance might be early events that contribute to weight gain and obesity development...
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504109/severe-traumatic-brain-injury-targeted-management-in-the-intensive-care-unit
#14
REVIEW
Nino Stocchetti, Marco Carbonara, Giuseppe Citerio, Ari Ercole, Markus B Skrifvars, Peter Smielewski, Tommaso Zoerle, David K Menon
Severe traumatic brain injury (TBI) is currently managed in the intensive care unit with a combined medical-surgical approach. Treatment aims to prevent additional brain damage and to optimise conditions for brain recovery. TBI is typically considered and treated as one pathological entity, although in fact it is a syndrome comprising a range of lesions that can require different therapies and physiological goals. Owing to advances in monitoring and imaging, there is now the potential to identify specific mechanisms of brain damage and to better target treatment to individuals or subsets of patients...
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504108/tuberculous-meningitis-and-hydrocephalus-in-filippino-de-medici
#15
Raffaella Bianucci, Philippe Charlier, Antonio Perciaccante, Otto Appenzeller, Donatella Lippi
No abstract text is available yet for this article.
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504107/jorge-sepulcre
#16
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504106/the-multiple-faces-of-artwork-diagnoses
#17
LETTER
Sharon N Farber
No abstract text is available yet for this article.
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504105/the-multiple-faces-of-artwork-diagnoses
#18
LETTER
Francesco Benedicenti, Andrea Superti-Furga
No abstract text is available yet for this article.
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504104/the-multiple-faces-of-artwork-diagnoses
#19
LETTER
Martino Ruggieri, Andrea D Praticò, Antonino Scuderi, Giovanni Sorge, Agata Polizzi
No abstract text is available yet for this article.
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28504103/detection-of-neurodegenerative-disease-using-olfaction
#20
Michael S Xydakis, Leonardo Belluscio
No abstract text is available yet for this article.
June 2017: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"